Key Points - Tanaka Precision Machinery has experienced significant short-term price increases, indicating potential short-term pullback risks [1] - Chuanjinno is facing high prices for sulfur, a key raw material, which may lead to increased production costs [1] - Songsheng Co. plans to establish a joint venture to develop digital energy products, including server power supplies and AI power supplies [1] - Beijing Keri has won a bid for a project with a value of 288 million yuan from the Southern Power Grid [1] - Transsion Holdings is projected to report a net profit of 2.584 billion yuan for 2025, reflecting a year-on-year decline of 53.43% [1] - Aibo Medical intends to acquire 68.31% of Demai Medical for 683 million yuan [1] - Wens Foodstuff Group plans to repurchase shares worth between 800 million and 1.2 billion yuan [1] - Gree Electric Appliances' Zhuhai Mingjun plans to reduce its stake by up to 2% [2] - Rizhao Port plans to issue corporate bonds with a total scale not exceeding 3 billion yuan [2] - Baibang Technology's subsidiary has renewed its agreement as an independent repair provider for Apple [2]

爱博医疗2月25日公告，公司拟使用并购贷款及自有资金收购德美联合（重庆）医疗科技有限公司（简 称"德美医疗"）68.31%股权，本次交易对价为6.83亿元。公司支付第一期股转款后，本次交易涉及的德 美医疗股权将全部完成办理工商变更登记，公司将享有作为目标公司股东的全部权利和权益，德美医疗 将成为公司控股子公司，纳入公司合并报表范围。本次交易不构成关联交易，未构成重大资产重组。 ...

（文章来源：证券日报） 证券日报网讯 2月25日，爱博医疗发布公告称，公司拟以68300.46万元并购贷款及自有资金收购德美联 合（重庆）医疗科技有限公司68.31%股权，支付第一期股转款后完成工商变更，德美医疗将纳入合并 报表。 ...

智通财经APP讯，爱博医疗(688050.SH)发布公告，公司("受让方")拟使用并购贷款及自有资金收购德美 联合(重庆)医疗科技有限公司(以下简称"德美医疗")68.31%股权，本次交易对价为人民币6.83亿元。 标的公司作为国内运动医学的头部企业，是国家高新技术企业和国家级专精特新"小巨人"企业，拥有 276项专利技术，建成了现代化生产基地与研发中心，具备技术研发实力与市场竞争力。标的公司已入 选第四批国家高值医用耗材集采A组，位列行业第一梯队；拥有丰富临床专家资源，销售网络覆盖全国 及东南亚、拉丁美洲、中东、欧洲等海外区域，在产品/技术研发、生产制造、境内外销售渠道等方面 与公司存在一定的协同性。 ...

Group 1: Suspension and Resumption of Trading - Zhiyang Innovation has terminated the planning of a major asset restructuring and resumed trading, planning to invest 300 million yuan in Lingming Photon [1] - FranTech's controlling shareholder is planning a share transfer, leading to a suspension of trading [2] - Huilong New Materials is planning a change in company control, resulting in a suspension of trading [2] Group 2: Share Buybacks - Wens Foodstuff Group plans to repurchase shares worth between 800 million to 1.2 billion yuan [3] Group 3: Mergers and Acquisitions - Aibo Medical intends to acquire 68.31% of Demai Medical for 683 million yuan; the target company is included in the fourth batch of national high-value medical consumables procurement and ranks in the first tier of the industry [4] Group 4: External Investments and Daily Operations - Shunhao Co., Ltd. has a subsidiary, Tiedao Chengguang, planning large-scale satellite production and network launch from 2031 to 2035, aiming to establish a large-scale space data center [5] - Huadian Technology has won a bid for an 827 million yuan EPC project for the Inner Mongolia Huadian Tengger 4×100 MW coal power project [6] - Shandong Haohua plans to invest 4.837 billion yuan in a project to enhance the quality and energy efficiency of its soda ash facilities [7] - Chuanjinno is rumored to be affected by the U.S. potentially prioritizing phosphorus and glyphosate as national security issues, though the actual impact on operations remains unclear [7] - Zhiguang Electric's subsidiary has won a bid for a 182 million yuan project from the Southern Power Grid [8] Group 5: Performance Changes - Chipbond Microelectronics expects a net profit of 290 million yuan in 2025, representing a year-on-year increase of 80.42%, driven by strong orders for high-end PCB equipment and optimization of product structure [9] - Haiguang Information anticipates a net profit of 620 million to 720 million yuan in the first quarter of 2026, a year-on-year increase of 22.56% to 42.32%, with a projected net profit of 2.54 billion yuan in 2025, up 31.66% year-on-year [9]

格隆汇2月25日丨爱博医疗(688050.SH)公布，公司拟使用并购贷款及自有资金收购德美联合(重庆)医疗 科技有限公司(以下简称"德美医疗""标的公司""标的资产"或"目标公司")68.31%股权，本次交易对价为 人民币68,300.46万元。公司支付第一期股转款后，本次交易涉及的德美医疗股权将全部完成办理工商变 更登记，公司将享有作为目标公司股东的全部权利和权益，德美医疗将成为公司控股子公司，纳入公司 合并报表范围。 标的公司作为国内运动医学的头部企业，是国家高新技术企业和国家级专精特新"小巨人"企业，拥有 276项专利技术，建成了现代化生产基地与研发中心，具备技术研发实力与市场竞争力。标的公司已入 选第四批国家高值医用耗材集采A组，位列行业第一梯队;拥有丰富临床专家资源，销售网络覆盖全国及 东南亚、拉丁美洲、中东、欧洲等海外区域，在产品/技术研发、生产制造、境内外销售渠道等方面与 公司存在一定的协同性。 ...

Core Viewpoint - Aibo Medical plans to acquire 68.31% equity of Demei United (Chongqing) Medical Technology Co., Ltd. for a total consideration of 683 million yuan, utilizing acquisition loans and its own funds [1] Group 1: Acquisition Details - The acquisition price for Demei Medical is set at 683 million yuan [1] - Aibo Medical aims to enhance its presence in the healthcare sector through this acquisition, focusing on collaboration in R&D, manufacturing, and sales channels [1] Group 2: Demei Medical Overview - Demei Medical has established itself as an international medical enterprise specializing in sports medicine, including the development, production, sales, and service of sports medicine implants, surgical tools, and rehabilitation equipment [1] - The core products of Demei Medical include full suture anchors, interface screws, ultra-strong sutures, reaming heads, arthroscopic cannulas, 4K ultra-precision camera systems, and adjustable braces, with sports medicine implants accounting for approximately 80% of its revenue [1] Group 3: Strategic Intent - Aibo Medical's core business focuses on the R&D and commercialization of biomedical materials and high-end medical devices [1] - The acquisition is expected to further improve Aibo Medical's performance and shareholder returns by leveraging synergies with Demei Medical [1]

每经头条（nbdtoutiao）——伤亡180万人！俄乌冲突四周年，陷入谈判死局、战场僵局、经济困局！谁 为战争买单 （记者 曾健辉） 每经AI快讯，爱博医疗2月25日晚间发布公告称，2026年2月25日，公司分别与德美医疗6名自然人股 东、北京德聚盈信息咨询中心（有限合伙），以及10名机构股东签署了《关于德美联合（重庆）医疗科 技有限公司股权转让协议》，拟使用并购贷款及自有资金收购德美医疗68.31%股权。公司支付第一期 股转款后，本次交易涉及的德美医疗股权将全部完成办理工商变更登记，公司将享有作为目标公司股东 的全部权利和权益，德美医疗将成为公司控股子公司，纳入公司合并报表范围。 ...

爱博医疗(688050.SH)公告称，公司拟使用并购贷款及自有资金收购德美联合（重庆）医疗科技有限公 司68.31%股权，交易对价为6.83亿元。标的公司已入选第四批国家高值医用耗材集采A组，位列行业第 一梯队；拥有丰富临床专家资源，销售网络覆盖全国及东南亚、拉丁美洲、中东、欧洲等海外区域，在 产品/技术研发、生产制造、境内外销售渠道等方面与公司存在一定的协同性。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

证券代码：688050 证券简称：爱博医疗 公告编号：2026-002 爱博诺德（北京）医疗科技股份有限公司 关于收购德美联合（重庆）医疗科技有限公司 部分股权的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、交易概述 重要内容提示： 爱博诺德（北京）医疗科技股份有限公司（以下简称"爱博医疗""公司" 或"受让方"）拟使用并购贷款及自有资金收购德美联合（重庆）医疗科技有限公 司（以下简称"德美医疗""标的公司""标的资产"或"目标公司"）68.31%股权， 本次交易对价为人民币 68,300.46 万元。公司支付第一期股转款后，本次交易涉及 的德美医疗股权将全部完成办理工商变更登记，公司将享有作为目标公司股东的 全部权利和权益，德美医疗将成为公司控股子公司，纳入公司合并报表范围。 标的公司作为国内运动医学的头部企业，是国家高新技术企业和国家级专 精特新"小巨人"企业，拥有 276 项专利技术，建成了现代化生产基地与研发中 心，具备技术研发实力与市场竞争力。标的公司已入选第四批国家高值医用耗材 集采 A 组，位列行业第 ...